Paul McBarron - Dec 21, 2023 Form 4 Insider Report for Cyclacel Pharmaceuticals, Inc. (CYCC)

Role
E. VP, Fin, CFO, COO and Secretary, Director
Signature
/s/ Paul McBarron
Stock symbol
CYCC
Transactions as of
Dec 21, 2023
Transactions value $
$6,252
Form type
4
Date filed
12/26/2023, 04:05 PM
Previous filing
Jul 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYCC Common Stock Purchase $6.25K +1.89K +5.99% $3.32 33.4K Dec 21, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYCC Warrants (right to buy) Purchase $0 +1.89K $0.00 1.89K Dec 21, 2023 Common Stock 1.89K $3.19 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person purchased unregistered shares of the Issuer's common stock in a private placement, pursuant to a Securities Purchase Agreement between the Reporting Person and the Issuer.
F2 Each share of common stock was purchased with an accompanying warrant at an aggregate purchase price of $3.315 per share and accompanying warrant.

Remarks:

E. VP, Fin, CFO, COO and Secretary